Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week we unpack a packed stretch of biotech headlines: Moderna writes a $2.25B check to settle its long-running mRNA lipid nanoparticle patent fight, the FDA ramps up enforcement against compounded GLP-1 telehealth clinics, and Eli Lilly tries to bypass insurers by selling obesity drugs directly through employers. We also zoom out on the shifting pharma leaderboard as Keytruda holds the top spot while GLP-1 megablocks surge, break down a wave of billion-dollar partnering deals from Alnylam and Sanofi, and dig into growing regulatory tension around gene therapy and gene editing, including uniQure’s Huntington’s program, PepGen’s surprise trial pause, and Prime Medicine testing whether the FDA might accept approval data from just two patients.
📣🎙️ TODAY’S PODCAST:
[ 0:34 ] Biotech Disruptions Overview
[ 2:11 ] Moderna Patent Settlement
[ 5:35 ] GLP-1 Weight Loss Drugs
[ 5:56 ] FDA Warning Letters Telehealth
[ 8:31 ] Lilly Employer Connect
[ 10:17 ] Keytruda Best-Selling Drug
[ 12:12 ] Cardiovascular Discovery Deal
[ 13:31 ] Sanofi Sino Biopharmaceutical Deal
[ 15:10 ] Huntington’s Gene Therapy
[ 18:41 ] Two Patient Gene Editing
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
